H.C. Wainwright raised the firm’s price target on Dianthus (DNTH) to $47 from $40 and keeps a Buy rating on the shares. The firm sees a “catalyst-rich” 2026 for the company.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus Therapeutics: Strong Financials and Promising Clinical Developments Justify Buy Rating
- Dianthus price target raised to $62 from $60 at Oppenheimer
- Dianthus Therapeutics Reports Q3 2025 Financial Results
- Dianthus Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating
- Dianthus reports Q3 EPS (97c), consensus (90c)